Abnormal expression of four novel molecular markers represents a highly aggressive phenotype in breast cancer. Immunohistochemical assay of p53, nm23, erbB-2, and cathepsin D protein
✍ Scribed by Han, Sehwan; Yun, Ik-Jin; Noh, Dong-Young; Choe, Kuk-Jin; Song, Sang-Yong; Chi, Je G.
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 248 KB
- Volume
- 65
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
✦ Synopsis
Background:
In view of the cumulative results to date, p53, nm23, erbb-2, and cathepsin d are the most promising investigational prognostic factors in breast cancer.
Objectives:
The clinical utility of these molecular markers to predict recurrence was evaluated.
Methods:
Archival pathology tissues of 100 breast cancer patients were analyzed by immunohistochemical assay. molecular biologic data were merged with clinicopathologic variables.
Results:
Thirty-two patients (32%) had recurrence of disease at a median follow-up of 48 months (range 26-72 months). investigational factor expression had statistical correlation for recurrence with increasing coexpression: one variable 20.6%, two variables 34.2%, three variables 47.1%, four variables 80.0% (p = 0.003). in univariate analysis, lymph node metastasis, tumor size, erbb-2 protein overexpression, and loss of nm23 protein expression were significant variables to determine recurrence; in multivariate analysis, node status and tumor size emerged as the most significant variables for recurrence.
Conclusions:
Coexpression of the studied investigational variables functioned as significant prognostic correlates for recurrence. these findings suggest that the studied investigational prognostic factors possess the ability to discriminate a highly aggressive phenotype in breast cancer.